Statements (32)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
|
gptkbp:approvalYear |
1992
|
gptkbp:approvedBy |
gptkb:United_States
|
gptkbp:ATCCode |
gptkb:C08CA01
|
gptkbp:bioavailability |
60-65%
|
gptkbp:CASNumber |
gptkb:88150-42-9
|
gptkbp:chemicalFormula |
C20H25ClN2O5
|
gptkbp:contraindication |
severe hypotension
allergy to amlodipine |
gptkbp:drugClass |
beta blocker
|
gptkbp:eliminationHalfLife |
30-50 hours
|
gptkbp:excretion |
urine
|
gptkbp:form |
10 mg
5 mg 2.5 mg |
gptkbp:genericName |
gptkb:amlodipine
|
gptkbp:halfLife |
30-50 hours
|
https://www.w3.org/2000/01/rdf-schema#label |
Norvasc
|
gptkbp:legalStatus |
prescription only
|
gptkbp:manufacturer |
gptkb:Pfizer
|
gptkbp:metabolism |
liver
|
gptkbp:pregnancyCategory |
C (US)
|
gptkbp:prescriptionStatus |
prescription only
|
gptkbp:routeOfAdministration |
oral
|
gptkbp:sideEffect |
edema
dizziness palpitations flushing |
gptkbp:usedFor |
hypertension
angina |
gptkbp:bfsParent |
gptkb:amlodipine
|
gptkbp:bfsLayer |
6
|